Evommune, Inc. balance sheet EVMN

As of Jun 30, 2026, Evommune, Inc. had total assets of $301.9 million and total liabilities of $24.4 million. Stockholders' equity was $277.6 million. It held $288.0 million in cash and investments against $8.6 million of total debt, net cash of $279.4 million. The current ratio, current assets divided by current liabilities, was 11.68.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Assets
Cash
60
48
44
27
Short-term investments
141
163
105
49
Long-term investments
87
96
67
—
Cash and investments
288
307
217
76
Total current assets
204
216
153
82
Property and equipment, net
2
2
1
1
Total assets
302
322
225
85
Liabilities and equity
Accounts payable
5
4
8
4
Total current liabilities
17
11
18
10
Total liabilities
24
18
19
11
Stockholders' equity
278
305
206
-183
Debt
Lease liabilities
9
9
2
1
Total debt
9
9
2
1
Net cash
279
298
215
75
Ratios
Current ratio
11.68x
20.36x
8.57x
7.87x
Debt to equity
0.03x
0.03x
0.01x
—
Return on equity
—
—
-33.50%
—
Return on assets
—
—
-30.62%
—
Book value per share
7.65
8.46
6.52
-117.78
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
EVMN (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
, Emerging growth company
SEC CIK
2044725

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.